The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience
Top Cited Papers
Open Access
- 10 April 2012
- journal article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 9 (4), e1001201
- https://doi.org/10.1371/journal.pmed.1001201
Abstract
Peter Doshi and colleagues describe their experience trying and failing to access clinical study reports from the manufacturer of Tamiflu and challenge industry to defend their current position of RCT data secrecy.This publication has 32 references indexed in Scilit:
- Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower ComplaintsPLoS Medicine, 2011
- The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public HealthAmerican Journal of Public Health, 2011
- Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort StudyPLoS Medicine, 2010
- Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trialsBMJ, 2010
- The Rosiglitazone Story — Lessons from an FDA Advisory Committee MeetingThe New England Journal of Medicine, 2007
- Characteristics and Impact of Drug Detailing for GabapentinPLoS Medicine, 2007
- Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical CompaniesPLoS Medicine, 2005
- Pfizer pleads guilty, but drug sales continue to soarBMJ, 2004
- Whistleblower charges drug company with deceptive practicesBMJ, 2003
- Science, Politics, and the Pharmaceutical Industry: Controversy and Bias in Drug RegulationTechnology and Culture, 1998